Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

by Robert Jenke, Nina Reßing, Finn K. Hansen, Achim Aigner, Thomas Büch
Published 2021-02-01

Editorial: Chemical Innovative Approaches in Cancer Molecular Medicine and Translational Clinical Research

by Rosaria Benedetti, Mariarosaria Conte, Carmela Dell'Aversana, Carmela Dell'Aversana, Finn K. Hansen, Clemens Zwergel
Published 2020-09-01

Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors

by Ana J. Rodrigues Moita, Jan J. Bandolik, Finn K. Hansen, Thomas Kurz, Alexandra Hamacher, Matthias U. Kassack
Published 2020-11-01

EDTA aggregates induce SYPRO orange-based fluorescence in thermal shift assay.

by Tobias Kroeger, Benedikt Frieg, Tao Zhang, Finn K Hansen, Andreas Marmann, Peter Proksch, Luitgard Nagel-Steger, Georg Groth, Sander H J Smits, Holger Gohlke
Published 2017-01-01

<i>In Vitro</i> Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)

by Annabelle Friedrich, Ann-Sophie Assmann, Lena Schumacher, Jana v. Stuijvenberg, Matthias U. Kassack, Wolfgang A. Schulz, Wynand P. Roos, Finn K. Hansen, Marc Pflieger, Thomas Kurz, Gerhard Fritz
Published 2020-07-01

Effects of novel HDAC inhibitors on urothelial carcinoma cells

by Aline Kaletsch, Maria Pinkerneil, Michèle J. Hoffmann, Ananda A. Jaguva Vasudevan, Chenyin Wang, Finn K. Hansen, Constanze Wiek, Helmut Hanenberg, Christoph Gertzen, Holger Gohlke, Matthias U. Kassack, Thomas Kurz, Wolfgang A. Schulz, Günter Niegisch
Published 2018-07-01